Savara (SVRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright reiterated a Buy rating on the stock and has a $6.00 price target.
Andrew Fein’s rating is based on Savara’s strategic advancements and potential market impact of their lead product, Molbreevi. The submission of the Biologics License Application (BLA) for Molbreevi, a recombinant human GM-CSF, to the FDA is a significant milestone. If approved, Molbreevi would be the first and only approved treatment for autoimmune pulmonary alveolar proteinosis (aPAP), potentially transforming the treatment landscape for this condition. The anticipated Priority Review could lead to a PDUFA date by the end of 2025, with a commercial launch potentially in early 2026.
Moreover, Savara’s proactive measures to ensure a successful launch, such as hiring a dedicated medical team and implementing a tele-educator initiative, demonstrate their commitment to reaching aPAP patients effectively. The company’s focus on identifying and targeting key medical centers and their efforts to facilitate accurate diagnosis through the aPAP ClearPath blood test are expected to enhance patient identification. These strategic initiatives, coupled with the high interest among patients, underpin Fein’s optimistic outlook and the Buy rating with a $6 price target.
In another report released yesterday, Wells Fargo also reiterated a Buy rating on the stock with a $8.00 price target.